BridgeMD
New treatment option for Hepatic Flexure Colon Cancer
Official title LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
ClinicalTrials.gov ID: NCT05923255
What this study is testing
- What it's testing
- The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age between 18-75 years old
- ASA classification ≤III
- Colon adenocarcinoma confirmed by endoscopy and pathological biopsy
- Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the...
- Preoperative clinical staging: TanyNanyM0
You likely can't join if
- Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection
- Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of...
- Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures
- History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell...
- Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery
- Patients unsuitable for or unable to tolerate laparoscopic surgery
See the full eligibility criteria
- Age between 18-75 years old
- ASA classification ≤III
- Colon adenocarcinoma confirmed by endoscopy and pathological biopsy
- Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the transverse colon)
- Preoperative clinical staging: TanyNanyM0
- Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent
- Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection
- Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and...
- Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures
- History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma
- Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery
- Patients unsuitable for or unable to tolerate laparoscopic surgery
- Pregnant or lactating women
- Patients with a history of psychiatric disorders
- Patients who have received neoadjuvant therapy prior to surgery
- Patients deemed unsuitable for the study by MDT discussion
- Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Bengbu, Anhui, China
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Fuzhou, Fujian, China
- Xiamen, Fujian, China
- Guangzhou, Guangdong, China
- Wuhan, Hubei, China
- Changsha, Hunan, China
- Nanjing, Jiangsu, China
- Nanchang, Jiangxi, China
- Jinan, Shandong, China
- Qingdao, Shandong, China
- Shanghai, Shanghai Municipality, China
- Xi’an, Shanxi, China
- Chengdu, Sichuan, China
- Xinjiang, Xinjiang, China
- Kunming, Yunnan, China
- Hangzhou, Zhejiang, China
- Jinhua, Zhejiang, China
- Ningbo, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bengbu, Anhui, China; Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Fuzhou, Fujian, China; Xiamen, Fujian, China; Guangzhou, Guangdong, China and 14 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.